Oragenics, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Oragenics, Inc. on December 18, 2013. The report details an unregistered sale of equity securities involving the conversion of a Convertible Promissory Note into common stock.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, or margin data. The specific financial event reported is the issuance of 698,241 shares of common stock to Intrexon Corporation. The conversion price was $2.82 per share, based on the closing price on the NYSE MKT prior to conversion.
Material Changes
The primary material change is the reduction of debt and increase in equity resulting from the conversion of a Convertible Promissory Note issued on September 30, 2013. This transaction served as partial consideration for a Technology Access Fee under an Exclusive Channel Collaboration Agreement regarding probiotics research and development.
Outlook, Risks, and Unusual Items
The Company relied on exemptions from federal registration under Section 4(2) and Regulation D (Rule 506) of the Securities Act of 1933. This reliance was based on the determination that the issuance did not involve a public offering, Intrexon is an accredited investor, and no general solicitation occurred. The filing includes exhibits related to the collaboration agreement and the convertible note.
Investor Verification Checklist
- Verify the total outstanding debt remaining after the conversion of the September 30, 2013 Note.
- Confirm the dilution impact of the 698,241 newly issued shares on existing shareholders.
- Review the terms of the Exclusive Channel Collaboration Agreement with Intrexon Corporation for future payment obligations.
- Check subsequent filings for any remaining cash obligations related to the Technology Access Fee.